primary cutaneous T-cell non-Hodgkin lymphoma
primary cutaneous T-cell non-Hodgkin lymphoma
Explore linked clinical trials. Standard reference: MONDO:000060799 results · Page 1 of 4
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | B-cell neoplasm, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, T-cell non-Hodgkin lymphoma, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, diffuse large B-cell lymphoma, epithelial neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, kidney cancer, kidney disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, renal cell carcinoma, urinary system disorder | Recruiting | Phase 1 | 2026-10-09 | NCT07195916 | |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) | Disease Attributes, Hemic and Lymphatic Diseases, Leukemia-Lymphoma, Adult T-Cell, Lymphadenopathy, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, T-cell leukemia, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-07 | NCT06035497 | |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, angioimmunoblastic T-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, mycosis fungoides, neoplasm, primary cutaneous T-cell lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-10-05 | NCT04234048 | |
| A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Not yet recruiting | Phase 2 | 2026-10-02 | NCT07854639 | |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-09-30 | NCT07192471 | |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-30 | NCT03278782 | |
| Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment | B-cell chronic lymphocytic leukemia, Chronic Disease, Cytopenia, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Male Urogenital Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell non-Hodgkin lymphoma, Urogenital Diseases, anemia, blood platelet disease, hairy cell leukemia, hematologic disorder, hemolytic anemia, hemolytic-uremic syndrome, immune system disorder, immunoproliferative disorder, kidney disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, thrombocytopenia, thrombotic microangiopathy, uremia, urinary system disorder | Recruiting | Not stated | 2026-09-22 | NCT01087333 | |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-09-18 | NCT05627245 | |
| Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-09-16 | NCT05944562 | |
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Not stated | 2026-09-14 | NCT07003100 | |
| CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT07022964 | |
| StrataCTX® as a Steroid Sparing Device | primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Not applicable | 2026-09-11 | NCT04087629 | |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, T-cell non-Hodgkin lymphoma, acute biphenotypic leukemia, acute leukemia, acute myeloid leukemia, acute undifferentiated leukemia, anemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myeloid leukemia, neoplasm, non-Hodgkin lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma | Not yet recruiting | Not applicable | 2026-09-10 | NCT07710781 | |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, T-cell non-Hodgkin lymphoma, acute biphenotypic leukemia, acute leukemia, acute myeloid leukemia, acute undifferentiated leukemia, anemia, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myeloid leukemia, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-10 | NCT05589896 | |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-09 | NCT06854653 | |
| A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma | mature T-cell and NK-cell non-Hodgkin lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-02 | NCT07758491 | |
| Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, folliculotropic mycosis fungoides, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-02 | NCT04930653 | |
| Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Sezary syndrome, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-08-27 | NCT04904146 | |
| Topical JAK-Inhibition of Early-Stage CTCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Not yet recruiting | Phase 2 | 2026-08-26 | NCT07781449 | |
| A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-08-18 | NCT06733441 | |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Colorectal Neoplasms, Hereditary Nonpolyposis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Hemic and Lymphatic Diseases, Infections, Lynch syndrome 2, Muir-Torre syndrome, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Sezary syndrome, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, adenocarcinoma, anaplastic large cell lymphoma, apocrine adenocarcinoma, basal cell carcinoma, basal cell neoplasm, basosquamous carcinoma, carcinoma, cutaneous neuroendocrine carcinoma, cystic, mucinous, and serous neoplasm, eccrine porocarcinoma, epithelial neoplasm, extramammary Paget disease, hereditary disease, hereditary neoplastic syndrome, hereditary skin disorder, hidradenocarcinoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant syringoma, mycosis fungoides, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, papillary adenocarcinoma, polyomavirus infectious disease, primary cutaneous T-cell non-Hodgkin lymphoma, primitive neuroectodermal tumor, sebaceous gland disorder, sebaceous gland neoplasm, signet ring cell carcinoma, skin basal cell carcinoma, skin disorder, skin neoplasm, skin squamous cell carcinoma, sweat gland cancer, sweat gland carcinoma, viral infectious disease, vulvar squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-08-13 | NCT02978625 | |
| Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-08-12 | NCT07754890 | |
| 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Hodgkins lymphoma, Immunoglobulin Light-chain Amyloidosis, Infections, Leukemia, B-Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myeloid, Chronic-Phase, Lymphadenopathy, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, acquired polycythemia vera, acute biphenotypic leukemia, acute myeloid leukemia, amyloidosis, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, central nervous system cancer, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, diffuse large B-cell lymphoma, essential thrombocythemia, follicular lymphoma, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, intraocular lymphoma, large-cell immunoblastic lymphoma, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, mast cell leukemia, mastocytosis, metabolic disease, monoclonal gammopathy, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, nervous system disorder, ocular cancer, plasma cell neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, prolymphocytic leukemia, proteostasis deficiencies, thrombocytosis disease, vascular disorder, vascular hemostatic disease, viral infectious disease | Active, not recruiting | Not stated | 2026-08-10 | NCT00935090 | |
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-07-31 | NCT04652960 | |
| Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, folliculotropic mycosis fungoides, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-07-31 | NCT03011814 |